How does alemtuzumab affect long-term graft and patient outcomes after deceased-donor kidney transplantation?

Nat Clin Pract Nephrol. 2005 Dec;1(2):74-5. doi: 10.1038/ncpneph0052.
No abstract available

MeSH terms

  • Alemtuzumab
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Neoplasm / therapeutic use*
  • Cadaver
  • Graft Survival
  • Humans
  • Immunosuppressive Agents / therapeutic use*
  • Kidney Transplantation*
  • Time Factors

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Neoplasm
  • Immunosuppressive Agents
  • Alemtuzumab